DDInter997 DDInter899
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Ivacaftor {u} (Compound) binds {v} (Gene) CYP3A4
Ivacaftor {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Ivacaftor {u} (Compound) causes {v} (Side Effect) Pleuritic pain
Ivacaftor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Ivacaftor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etonogestrel
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Avapritinib
Ivacaftor {u} may lead to a major life threatening interaction when taken with {v} Fluconazole
Ivacaftor {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Ivacaftor (Compound) binds CYP3A4 (Gene)
Ivacaftor (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Ivacaftor (Compound) causes Pleuritic pain (Side Effect)
Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Modafinil
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Ivacaftor may lead to a major life threatening interaction when taken with Fluconazole
Ivacaftor may lead to a major life threatening interaction when taken with Crizotinib